Scientific Publications Search Search Author Release Date Research Group Search Sort by RelevanceFrom A-ZAuthored onDate/Time RangeRelease date Order AscDesc Akalin, Altuna Dr. (1) Costanza, Mariantonia Dr. (1) Franke, Vedran Dr. (1) Hinze, Christian Dr. med. Dipl.-Math. (1) Hübner, Norbert Prof. Dr. (1) Janz, Martin Dr. (5) Kolesnichenko, Marina Dr. (1) Leutz, Achim Prof. Dr. (1) Patone, Giannino Dr. (1) Pezzutto, Antonio Prof. Dr. (1) Scheidereit, Claus Prof. Dr. (3) Sczakiel, Henrike (1) Selbach, Matthias Prof. Dr. (1) (-) Daumke, Oliver Prof. Dr. (1) (-) Mathas, Stephan Dr. (8) 1999 (1) 2000 (1) 2001 (1) 2002 (5) 2003 (1) 2004 (2) (-) 2005 (2) 2006 (4) (-) 2007 (3) 2008 (4) 2009 (3) 2010 (3) 2011 (4) 2012 (1) 2013 (1) 2014 (2) 2015 (5) 2016 (2) 2017 (3) (-) 2018 (1) (-) 2019 (2) 2020 (2) 2021 (3) 2022 (4) 2024 (1) AG Müller/Dechend (ECRC) (1) Anchored Signalling (1) Bioinformatics and Omics Data Science (1) (-) Biology of Malignant Lymphomas (8) Developmental Biology / Signal Transduction (1) Genetics and Genomics of Cardiovascular Diseases (1) Genome Diversification & Integrity (1) Hypertension-caused End-Organ Damage (1) Hypertension-Mediated End-Organ Damage (1) In Situ Structural Biology (1) Proteome Dynamics (1) Structural Biology of Membrane-Associated Processes (16) Systems Biology of Gene Regulatory Elements (1) 8 Results: Active Filter: Daumke, Oliver Prof. Dr.Mathas, Stephan Dr.Biology of Malignant Lymphomas2005200720182019 Sort: Result score Newest to oldest Oldest to newest January 01, 2005 / Blood A rapamycin derivative (everolimus) controls proliferation through down-regulation of truncated CCAAT enhancer binding protein beta and NF-kappaB activity in Hodgkin and anaplastic large cell lymphomas F. Jundt N. Raetzel C. Mueller C.F. Calkhoven K. Kley S. Mathas A. Lietz A. Leutz B. Doerken March 01, 2007 / Hum Immunol Dendritic cell maturation stage determines susceptibility to the proteasome inhibitor bortezomib M. Subklewe K. Sebelin-Wulf C. Beier A. Lietz S. Mathas B. Doerken A. Pezzutto May 01, 2007 / Br J Haematol Loss of bHLH transcription factor E2A activity in primary effusion lymphoma confers resistance to apoptosis A. Lietz M. Janz M. Sigvardsson F. Jundt B. Doerken S. Mathas October 01, 2007 / Hematol Oncol Clin North Am The pathogenesis of classical Hodgkin's lymphoma: a model for B-cell plasticity S. Mathas August 25, 2005 / Blood Elevated NF-kappaB p50 complex formation and Bcl-3 expression in classical Hodgkin, anaplastic large cell, and other peripheral T-cell lymphomas S. Mathas K. Joehrens S. Joos A. Lietz F. Hummel M. Janz F. Jundt I. Anagnostopoulos K. Bommert P. Lichter H. Stein C. Scheidereit B. Doerken September 01, 2018 / Leukemia The AP-1-BATF and -BATF3 module is essential for growth, survival and TH17/ILC3 skewing of anaplastic large cell lymphoma N. Schleussner O. Merkel M. Costanza H.C. Liang F. Hummel C. Romagnani P. Durek I. Anagnostopoulos M. Hummel K. Jöhrens A. Niedobitek P.R. Griffin R. Piva H.L. Sczakiel W. Woessmann C. Damm-Welk C. Hinze D. Stoiber B. Gillissen S.D. Turner E. Kaergel L. von Hoff M. Grau G. Lenz B. Dörken C. Scheidereit L. Kenner M. Janz S. Mathas June 01, 2019 / Leukemia Global long terminal repeat activation participates in establishing the unique gene expression programme of classical Hodgkin lymphoma B. Edginton-White P. Cauchy S.A. Assi S. Hartmann A.G. Riggs S. Mathas P.N. Cockerill C. Bonifer March 28, 2019 / Blood Autocrine LTA signaling drives NF-κB and JAK-STAT activity and myeloid gene expression in Hodgkin lymphoma L. von Hoff E. Kärgel V. Franke E. McShane K.W. Schulz-Beiss G. Patone N. Schleussner M. Kolesnichenko N. Hübner O. Daumke M. Selbach A. Akalin S. Mathas C. Scheidereit
January 01, 2005 / Blood A rapamycin derivative (everolimus) controls proliferation through down-regulation of truncated CCAAT enhancer binding protein beta and NF-kappaB activity in Hodgkin and anaplastic large cell lymphomas F. Jundt N. Raetzel C. Mueller C.F. Calkhoven K. Kley S. Mathas A. Lietz A. Leutz B. Doerken
March 01, 2007 / Hum Immunol Dendritic cell maturation stage determines susceptibility to the proteasome inhibitor bortezomib M. Subklewe K. Sebelin-Wulf C. Beier A. Lietz S. Mathas B. Doerken A. Pezzutto
May 01, 2007 / Br J Haematol Loss of bHLH transcription factor E2A activity in primary effusion lymphoma confers resistance to apoptosis A. Lietz M. Janz M. Sigvardsson F. Jundt B. Doerken S. Mathas
October 01, 2007 / Hematol Oncol Clin North Am The pathogenesis of classical Hodgkin's lymphoma: a model for B-cell plasticity S. Mathas
August 25, 2005 / Blood Elevated NF-kappaB p50 complex formation and Bcl-3 expression in classical Hodgkin, anaplastic large cell, and other peripheral T-cell lymphomas S. Mathas K. Joehrens S. Joos A. Lietz F. Hummel M. Janz F. Jundt I. Anagnostopoulos K. Bommert P. Lichter H. Stein C. Scheidereit B. Doerken
September 01, 2018 / Leukemia The AP-1-BATF and -BATF3 module is essential for growth, survival and TH17/ILC3 skewing of anaplastic large cell lymphoma N. Schleussner O. Merkel M. Costanza H.C. Liang F. Hummel C. Romagnani P. Durek I. Anagnostopoulos M. Hummel K. Jöhrens A. Niedobitek P.R. Griffin R. Piva H.L. Sczakiel W. Woessmann C. Damm-Welk C. Hinze D. Stoiber B. Gillissen S.D. Turner E. Kaergel L. von Hoff M. Grau G. Lenz B. Dörken C. Scheidereit L. Kenner M. Janz S. Mathas
June 01, 2019 / Leukemia Global long terminal repeat activation participates in establishing the unique gene expression programme of classical Hodgkin lymphoma B. Edginton-White P. Cauchy S.A. Assi S. Hartmann A.G. Riggs S. Mathas P.N. Cockerill C. Bonifer
March 28, 2019 / Blood Autocrine LTA signaling drives NF-κB and JAK-STAT activity and myeloid gene expression in Hodgkin lymphoma L. von Hoff E. Kärgel V. Franke E. McShane K.W. Schulz-Beiss G. Patone N. Schleussner M. Kolesnichenko N. Hübner O. Daumke M. Selbach A. Akalin S. Mathas C. Scheidereit